News

We’ve partnered with C-Bond Systems to better supply the automotive industries!

We’ve  entered into an exclusive, nationwide distribution agreement with C-Bond Systems for use of MB-10 Tablets, an EPA-registered disinfectant (Reg No.70060-19-46269) to help in the fight against COVID-19. COVID-19 is caused by SARS-CoV-2. This product kills similar viruses and therefore, according to the EPA Guidelines On Emerging Pathogens, can be used against SARS-CoV-2 when used in accordance with the directions for use against MVM on hard, nonporous surfaces. With this new agreement, C-Bond will gain exclusive rights to sell the tablets within the verticals that it serves.

“We’re excited to be working with new partners to deliver the simple and sensible disinfection results that we’re known for in the research and clinical markets to an expanded customer-base.” Said Tim Hidell, President of Quip Laboratories. “MB-10 Tablets have a proven track record as a cost-effective disinfectant across a wide range of industries, and we look forward to helping C-Bond in that goal for their clientele.”

MB-10 tablets are registered as a broad spectrum hospital disinfectant that is effective against a wide range of bacteria and viruses, and are safe for hard, non-porous surfaces such as glass, plastics, sealed fiberglass, and a wide range of metals, without leaving residues or odor. MB-10 Tablets also protect without staining or discoloring.

“The applications for this EPA-registered product align well with our current customer base, presenting an exciting cross-selling opportunity,” said Scott R. Silverman, Chairman and Chief Executive Officer of C-Bond Systems. “Well after the COVID-19 pandemic subsides, we expect the desire to regularly and thoroughly disinfect hard surfaces to continue to surge. This product perfectly meets the evolving needs of today’s marketplace.

“Leveraging our ever-expanding customer base within the transportation sector, we believe we are uniquely positioned for success with the introduction of this new disinfectant. I look forward to continued operational execution in driving forward our core mission – to make the world a safer place – with the addition of this exciting new product,” concluded Silverman.